Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Operating Income: 2009-2024

Historic Operating Income for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to -$497.9 million.

  • Madrigal Pharmaceuticals' Operating Income rose 2.00% to -$114.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$307.5 million, marking a year-over-year increase of 43.90%. This contributed to the annual value of -$497.9 million for FY2024, which is 30.85% down from last year.
  • As of FY2024, Madrigal Pharmaceuticals' Operating Income stood at -$497.9 million, which was down 30.85% from -$380.5 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Operating Income ranged from a high of -$206.7 million in FY2020 and a low of -$497.9 million during FY2024.
  • Moreover, its 3-year median value for Operating Income was -$380.5 million (2023), whereas its average is -$390.6 million.
  • Data for Madrigal Pharmaceuticals' Operating Income shows a maximum YoY slumped of 117.61% (in 2020) over the last 5 years.
  • Over the past 5 years, Madrigal Pharmaceuticals' Operating Income (Yearly) stood at -$206.7 million in 2020, then fell by 17.33% to -$242.5 million in 2021, then fell by 21.07% to -$293.6 million in 2022, then fell by 29.61% to -$380.5 million in 2023, then plummeted by 30.85% to -$497.9 million in 2024.